Outcomes in Stage III vs Limited Stage IV Non-Small Cell Lung Cancer
Author Information
Author(s): Cheruvu Praveena, Metcalfe Su K, Metcalfe Justin, Chen Yuhchyau, Okunieff Paul, Milano Michael T
Primary Institution: University of Rochester Medical Center
Hypothesis
Patients treated with SBRT for limited metastases have comparable outcomes with those treated with curative-intent radiation for Stage III NSCLC.
Conclusion
Patients with limited stage IV NSCLC treated with aggressive local therapy have better outcomes compared to those with stage III NSCLC.
Supporting Evidence
- 88% of patients had KPS ≥ 80%.
- 30% had more than 5% weight loss.
- 95% were smokers.
- 5-year overall survival for stage III was 7%, for initial stage IV was 14%, and for recurrent stage IV was 27%.
- Patients with limited metastases had significantly better survival compared to those with extensive metastases.
Takeaway
Some patients with stage IV lung cancer can do just as well as those with stage III if they have fewer tumors and get special treatment.
Methodology
Retrospective review of NSCLC patients treated with curative-intent radiotherapy from 2000-2008.
Potential Biases
Potential selection bias due to the retrospective design and varying treatment regimens.
Limitations
Retrospective nature, heterogeneity of treatments, and small patient numbers in some subgroups.
Participant Demographics
Patients aged 35-85 years, 88% had KPS ≥ 80%, 95% were smokers.
Statistical Information
P-Value
p < 0.00001
Statistical Significance
p < 0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website